



Mechanisms and pharmacological applications of ferroptosis: a narrative review

Jing-Jing Zhang^{1,2#}, Jing Du^{3#}, Ni Kong², Guang-Yu Zhang², Meng-Zhen Liu², Chong Liu²

¹Department of Clinical Pharmacology, Weifang People's Hospital, Weifang, China; ²Department of Pharmacology, Second Military Medical University, Shanghai, China; ³Department of Basic Medicine, School of Pharmacology, Jining Medical College, Rizhao, China

Contributions: (I) Conception and design: All authors; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Chong Liu. Department of Pharmacology, Second Military Medical University, 325 Guohe Road, Shanghai 200433, China.
Email: wanlc2004@aliyun.com.

Objective: We aimed at comprehensively analyzing ferroptosis regulation and its potential role in the treatment of associated diseases.

Background: Ferroptosis is a recently discovered form of cell death that involves small molecule-induced oxidative cell death. This process is usually accompanied by large amounts of iron accumulation and lipid peroxidation. Ferroptosis inducers directly or indirectly affect glutathione peroxidase (GPXs) through different pathways. Disturbances in GPXs result in suppressed cellular antioxidant capacities, accumulation of lipid reactive oxygen species (ROS) and oxidative cell death. It has been reported that ferroptosis is closely associated with the pathophysiological processes of many diseases, including tumors, nervous system diseases, ischemia-reperfusion injury, kidney injury and iron metabolism diseases among others.

Methods: First, we reviewed the mechanisms of ferroptosis, with emphasis on the characteristics and functions of ferroptosis in multiple pathways. Then, inducers and inhibitors of ferroptosis were reviewed, and their mechanisms of action elucidated. Finally, ferroptosis-associated pathophysiological processes of various diseases were reviewed.

Conclusions: Ferroptosis is associated with the occurrence and development of various diseases. Elucidation of the mechanisms involved in ferroptosis will inform new therapeutic targets and strategies for these diseases.

Keywords: Ferroptosis; glutathione peroxidase; lipid peroxidation; iron accumulation

Submitted Mar 31, 2021. Accepted for publication Aug 18, 2021.

doi: 10.21037/atm-21-1595

View this article at: <https://dx.doi.org/10.21037/atm-21-1595>

Introduction

Cell death marks the end of cell life and is an inevitable link in the process of life in a physiological or pathological state (1). Traditionally, apoptosis and necrosis were recognized as the two main forms of cell death. However, recently, it has been reported that autophagy, necrotic apoptosis, ferroptosis are also forms of cell death, with unique biological processes and pathophysiological characteristics. Ferroptosis, an iron-dependent form of

non-apoptotic cell death, is characterized by accumulation of lipid ROS. This mode of cell death is different from other forms of previously reported cell death by the fact that it does not induce nuclear morphological changes, DNA fragmentation, and caspase-3 activation. In addition, ferroptosis cannot be reversed by caspase inhibitors. Erastin, which was discovered in 2003, has selective lethal effects on RAS-expressing cancer cells (2). Yang *et al.* and Yagoda *et al.* reported that this form of cell death is not inhibited

Table 1 The common inducers of ferroptosis

Inducers	Mechanisms	References
Erastin	Inhibit system Xc-	(5)
Sorafenib	Inhibit system Xc-	(10)
Sulfasalazine	Inhibit system Xc-	(5)
CD8+ T cells	Inhibit system Xc-	(11)
RSL3	Inhibit GPX4	(12)
ML162, ML210	Inhibit GPX4	(12,13)
DPI7, DPI10	Inhibit GPX4	(12)
Artemisinin derivatives	Inhibit GPX4	(14)
FIN56	Inhibit GPX4	(15)
FINO2	Iron oxidation and inactivate GPX4 inactivate GPX4	(16)
BSO, Ace	Reduce GSH level	(12,17)
Siramesine, Lapatinib	Increase of accumulation of iron	(18)
Neutrophils	Increase lipid-based ROS	(19)

RSL3, (1S,3R)-RSL-3; FIN, ferroptosis inducing compound; BSO, L-buthionine sulfoximine; Ace, acetaminophen; GSH, glutathione; system Xc-, cystine-glutamate transporter receptor; GPX4, glutathione peroxidase 4; ROS, reactive oxygen species.

by iron-chelating agents (3,4). Moreover, the RSL3 factor is implicated in this form of cell death. In 2012, Dixon *et al.* formally named this form of iron-dependent cell death as ‘ferroptosis’ (5). Ferroptosis differs from necrosis, apoptosis, and autophagy in both morphological effects and function. For instance, ferroptosis does not exhibit the morphological characteristics that are associated with necrosis, including swelling of the cytoplasm and organelles. Furthermore, it does not exhibit morphological characteristics of the typical apoptotic process, including chromatin condensation, cell contraction, formation of apoptotic bodies, and cytoskeleton disintegration. Moreover, ferroptosis is not characterized by formation of classical closed bilayer membrane structures. Ferroptosis is characterized by significant mitochondrial shrinkage with increased membrane densities and a reduction in, or vanishing of mitochondrial cristae (6). Ferroptosis plays an important role in the occurrence and development of various diseases of the nervous system, brain, liver, kidneys, lungs, and other related diseases. Therapeutic targets and strategies for various diseases have been investigated by regulating cell ferroptosis (7). Notably, ferroptosis inducers are used to kill malignant tumor cells while ferroptosis inhibitors are effective in the treatment of several diseases (8,9). Inducers and inhibitors of ferroptosis are summarized in *Table 1* and *Table 2*, respectively.

The discovery of ferroptosis has enhanced our knowledge on disease progression and treatment. We review recent research progress on the mechanisms and diseases associated with ferroptosis. The aim of this study was to elucidate on the mechanisms of ferroptosis and regulation of ferroptosis as a new treatment strategy for associated diseases.

This article is reported in accordance with the Narrative Review reporting checklist (available at <https://dx.doi.org/10.21037/atm-21-1595>).

Mechanisms of ferroptosis

The regulatory mechanisms of ferroptosis can be divided into three categories including: regulation by iron metabolism, regulation by glutathione peroxidase 4 (GPX4) and regulation by lipid metabolism. Ferroptosis suppressor protein 1 (FSP1)-CoQ10-NAD(P)H pathway and tetrahydrobiopterin (BH4)-dihydrofolate reductase (DHFR) pathway exist as independent parallel systems and interact with GPX4 and glutathione to inhibit phospholipid peroxidation and ferroptosis.

The FSP1-CoQ10-NAD(P)H pathway

The apoptosis-inducing factor mitochondria-associated 2

Table 2 The common inhibitors of ferroptosis

Inhibitors	Mechanisms	References
Fer-1	Inhibit lipid peroxidation	(5)
Liproxstatin-1	Inhibit lipid peroxidation	(20)
SRS11–9, SRS16–86	Inhibit lipid peroxidation	(1)
Vitamin E	Inhibit lipid peroxidation	(21)
Phenoxazin	Inhibit lipid peroxidation	(22)
Nitroxide-based compounds	Inhibit lipid peroxidation	(23)
DFO	Inhibit accumulation of iron	(1)
Deferoxamine mesylate	Inhibit accumulation of iron	(1)
2,2'-pyridine	Inhibit accumulation of iron	(1)
Compound 968	Glutaminase inhibitor	(24)
Amino-oxyacetic acid	Glutaminase inhibitor	(24)
Rosiglitazone	ACSL4 inhibitor	(25)
Allosteric GPX4 activators	Increases GPX4 activity	(26)

Fer-1, Ferrostatin-1; DFO, deferoxamine; GPX4, glutathione peroxidase 4; ACSL4, acyl-CoA synthetase long-chain family member 4.

(AIFM2, also known as FSP1), a traditional mitochondrial apoptosis inducer, plays an important role in ferroptosis (27,28). FSP1 is an effective anti-ferroptosis factor that uses the synthetic lethal CRISPR-Cas9 approach (27). Overexpression of FSP1 significantly protects cells from ferroptosis. Moreover, a classical cardamom acylation modification sequence at the N-terminal of FSP1 has been reported, indicating that FSP1 may be associated with lipid biomolecules. FSP1 catalyzes CoQ10 regeneration through NAD(P)H to inhibit ferroptosis. As an independent system, the FSP1-CoQ10-NAD(P)H pathway coordinates with GPX4 and GSH to inhibit ferroptosis and phospholipid peroxidation. Furthermore, FSP1 suppresses lipid oxidation by reducing CoQ10 and, subsequently, inhibiting ferroptosis (27,28). These findings provide a basis for the development of therapeutic drugs that target ferroptosis in cancer cells.

The BH4-DHFR pathway

BH4 is a potent radical-trapping antioxidant that is regenerated by DHFR and protects lipids from peroxidation (29). Kraft *et al.* investigated a cohort of genes that antagonize ferroptotic cell death, including GTP cyclohydrolase-1 (GCH1) and its metabolic derivatives tetrahydrobiopterin/dihydrobiopterin (BH4/BH2) through genome-wide activation screening. The synthesis of BH4/

BH2 by GCH1-expressing cells causes lipid remodeling, and suppresses ferroptosis by selectively preventing the depletion of phospholipids with two polyunsaturated fatty acyl tails (30). Therefore, the GCH1-BH4-phospholipid axis acts as a major regulatory pathway for ferroptosis resistance, by regulating the endogenous production of the BH4 antioxidant, levels of CoQ10, and peroxidation of unusual phospholipids with two polyunsaturated fatty acyl tails (30). This is a unique mechanism of ferroptosis protection that is independent of the GPX4/glutathione system.

The P53 pathway

P53 is a tumor suppressor gene that affects the cell cycle, senescence, and apoptosis. In addition, it has positive or negative regulatory effects on ferroptosis. Mechanisms of P53 in regulation of ferroptosis majorly occur through transcription-dependent or transcription-independent processes. Acetylation deficient P53 mutants promote ferroptosis. Jiang *et al.* reported that after P53 activation, 90% of cells died from lipid ROS, indicating that P53 activation suppresses the antioxidant capacity of cells. Ferrostatin-1, a ferroptosis inhibitor, was found to significantly decrease cell death rate, implying that P53 induces ferroptosis (31). They further reported that P53 inhibits cystine uptake and sensitizes cells to ferroptosis by

suppressing the expression of SLC7A11, a key component of the cystine/glutamate antiporter. Inhibitory effects of P53 suppresses GPX4 activity, and ultimately induces cell ferroptosis (31,32). Studies have used xenotransplantation models to investigate the unique mechanisms of P53-induced ferroptosis (33). It was found that P53 indirectly activates SLC7A11 function through transcriptional inhibition of arachidonate lipoxygenase 12 (ALOX12). This activation causes ALOX12-dependent ferroptosis under lipid ROS stress. These findings indicate that ALOX12 is essential for P53-mediated ferroptosis. Moreover, the P53-SAT1 (spermine N1-acetyltransferase 1)-ALOX15 (arachidonate lipoxygenase 15) pathway is involved in ferroptosis regulation (34). Glutamine metabolism is another target for P53-mediated ferroptosis. An African-specific single nucleotide polymorphism Ser47 variant in P53 has been shown to weaken P53 functions in transactivated target proteins, including glutaminase 2 (GLS2), thereby inducing cell death. In addition, the expression of P53 can inhibit ferroptosis (35). Tarangelo *et al.* (36) reported that P53 suppresses cell sensitivity to ferroptosis. The process of reducing sensitivity to ferroptosis requires the involvement of cyclin-dependent kinase inhibitor 1A/P21 (CDKN1A). These findings indicate that the P53-P21 axis negatively regulates ferroptosis, and that P53 can inhibit ferroptosis by promoting dipeptidyl peptidase-4 (DPP4) translocation to the nucleus. The expression of P53 is correlated with suppressed iron deposition in colorectal cancer cells (37). Therefore, P53 may be a regulator of ferroptosis and the specific mechanisms should be further investigated.

The Glutathione (GSH)/GPX4 pathway

GPX4 plays a key role in ferroptosis occurrence, mainly by inhibiting the formation of lipid peroxides. GPX4 inhibits cell death by converting GSH to oxidized glutathione (GSSG) and by reducing cytotoxic lipid peroxides (L-OOH) to their corresponding alcohols (L-OH). Therefore, inhibition of GPX4 activity can lead to lipid peroxides accumulation, resulting in ferroptosis. Ferroptosis inducers, including RSL3 and erastin cause an increase in lipid reactive oxygen species, however, their mechanisms of action differ. To decrease glutathione levels, Erastin inhibits cysteine absorption by suppressing the Xc-pathway. Yang *et al.* (12) investigated the mechanism of RSL3 and reported that RSL3, DPI7 and DPI10 directly act on GPX4, thereby reducing the antioxidant capacity of cells, which leads to accumulation of lipid ROS and to ferroptosis. The mevalonate pathway

(MVA) affects GPX4 synthesis by regulating selenocysteine tRNA maturation, thereby regulating ferroptosis occurrence. Isopentene pyrophosphate (IPP) and CoQ10 are two important products of the MVA pathway (38,39).

System Xc- pathway

System Xc- is an amino acid antiporter that is widely distributed in the phospholipid bilayer, an important part of the antioxidant system that contains a heterodimer of SLC7A11 and SLC3A2 subunits (40), which play an important role in negative regulation of ferroptosis. In the system Xc- pathway, cystine and glutamate are transported in and out of cells at a ratio of 1:1. Extracellular cystine is absorbed into the cell and is rapidly reduced to cysteine, which is involved in glutathione synthesis. A decrease in GSH causes a decrease in GPX4 activity (3). GPX4 catalyzes hydrogen peroxide and hydroperoxide degradation and inhibits lipid ROS production, with glutathione as an important cofactor. Therefore, this pathway affects GSH synthesis by inhibiting the activity of system Xc- and cysteine absorption. Suppressed GPX4 activity inhibits cellular antioxidant capacity and leads to lipid ROS accumulation, ultimately causing oxidative damage and ferroptosis (41). P53 down-regulates the expression of SLC7A11, which inhibits cystine uptake, affecting GPX4 activity, ultimately leading to decreased antioxidant capacity, lipid ROS accumulation, and ferroptosis (32).

Iron metabolism pathway

Iron, an important trace element in the body, mainly exists as a divalent iron and trivalent iron. Abnormal iron distribution and concentrations in the body can affect normal physiological processes. Non-heme iron in food is mainly in the Fe³⁺ form, which is insoluble, and should be reduced to Fe²⁺ for absorption. Fe³⁺ binds transferrin (TF) in serum, is recognized by transferrin receptor 1 (TFR1) on the cell membrane and is then internalized by endocytosis (42,43). Fe³⁺ is reduced to Fe²⁺, which is stored in an unstable iron pool (LIP) under the mediation of divalent metal ion transporter 1 (DMT1) or zinc-iron regulatory protein family 8/14 (ZIP8/14). The iron-efflux protein solute carrier family 40 member 1 (SLC40A1/ferroportin1/FPN) extrudes iron into the extracellular space, as excess Fe²⁺ is re-oxidized to Fe³⁺ by ferroxidases and the iron cycle in the body strictly controls cellular iron homeostasis (43,44).

Heat shock protein β -1 (HSPB1) can suppress intracellular

iron concentrations by inhibiting TRF1 expression. Therefore, overexpression of HSPB1 inhibits ferroptosis (45). The iron-storage protein, ferritin, consists of 24 subunits of ferritin light chain (FTL) and ferritin heavy chain 1 (FTH1), which can be degraded by lysosomes to increase free iron levels. Expression of iron response element-binding protein 2 (IREB2), the main transcriptional factor that inhibits iron metabolism, elevates the expression of FTL and FTH1, suppresses ferrous ion concentrations and the production of lipid reactive oxygen species in cells (46). Heme oxygenase-1 (HO-1) promotes erastin-induced ferroptosis by supplementing iron (47). These findings indicate that ferritin regulation and iron metabolism homeostasis are important regulatory mechanisms of ferroptosis.

Lipid metabolism pathway

Ferroptosis is closely associated with lipid metabolism imbalance, and accumulation of iron-dependent lipid ROS is involved in all ferroptotic pathways. Polyunsaturated fatty acids (PUFAs) are highly sensitive to lipid peroxidation. PUFAs form lipid hydroperoxides through enzymatic or non-enzymatic oxidation, therefore, they are important ferroptotic elements (48). Phosphatidylethanolamine (PE) containing arachidonic acid (AA) or its metabolic product, adrenic acid, are the key phospholipids that are implicated in cell ferroptosis (49). Acyl-CoA synthetase long-chain family member 4 (ACSL4) and phospholipid choline acyltransferase 3 (LPCAT3) are involved in PE biosynthesis and remodeling, activation of polyunsaturated fatty acids and affect the transmembrane properties of polyunsaturated fatty acids. The expression of ACSL4 enhances sensitivity to ferroptosis-inducing compounds (25). Therefore, suppression of the expression of ACSL4 and LPCAT3 reduces intracellular lipid peroxide substrate accumulation, which inhibits ferroptosis. Moreover, PUFA-PE can play an oxidation role under catalysis by lipoxygenase (LOX), thus inducing cell ferroptosis. Therefore, lipid reactive oxygen species-mediated cell damage is essential for ferroptosis (25).

The ATG5-ATG7-Nuclear receptor coactivator 4 (NCOA4) pathway

Autophagy is a self-protecting cellular catabolic pathway that relies on lysosomes (50). Although autophagic responses promote survival, excessive autophagy, especially selective autophagy, promotes ferroptosis by promoting iron accumulation and lipid peroxidation (51). The most

classical pathway is the ATG5-ATG7-NCOA4 pathway (52). Autophagic degradation of ferritin plays an important role in maintaining iron homeostasis (53). NCOA4 has been identified by quantitative proteomics to be a direct cargo receptor for autophagic degradation of ferritin in lysosomes. NCOA4-dependent iron phages promote ferroptosis by releasing free iron from ferritin. Cigarette smoke promotes unstable iron accumulation through NCOA4-mediated iron autophagy, leading to phospholipid peroxidation and ferroptosis in human lung epithelial cells (54). The significance of autophagy to ferroptosis has been investigated in human cancer cell lines and mouse tumor models (55). It was found that autophagy-dependent ferroptosis mediates tumor-associated macrophage polarization and pancreatic tumor growth as well as progression through KRAS protein secretion.

Other pathways

Voltage-dependent anion channel (VDAC) is a transmembrane channel for transporting ions and metabolites and plays an important role in ferroptosis regulation (56). The effects of erastin on VDAC causes mitochondrial dysfunction, leading to the release of several oxides, eventually causing iron-mediated cell death (4). In addition, ferroptosis occurrence is regulated by several other pathways, such as glutamine metabolic pathway, p62-Keap1-NRF2 pathway and squalene activity (24,57,58). The nuclear factor erythroid 2-related factor 2 (NRF2), which has been implicated in the p62-Keap1-NRF2 pathway, is a key regulator of antioxidant responses. NRF2 plays a key role in protecting hepatocellular carcinoma (HCC) cells against ferroptosis. Furthermore, p62 expression prevents NRF2 degradation and enhances the subsequent NRF2 nuclear accumulation through inactivation of Kelch-like ECH-associated protein 1 (57). Squalene is a metabolite with antioxidant-like properties. Squalene monooxygenase (SQLE) catalyzes the oxidation of squalene to 2,3-oxidosqualene in the cholesterol synthesis pathway. Downregulation of SQLE results in accumulation of the upstream metabolite, squalene. Garcia-Bermudez *et al.* reported that squalene altered cellular lipid profiles and protected cancer cells from ferroptotic cell death by downregulating SQLE expression in ALK+ anaplastic large cell lymphoma (ALCL) cell lines and primary tumors (58). These pathways can effectively regulate the formation of intracellular iron ions and reactive oxygen species, thus playing a regulatory role in ferroptosis.

Pharmacological applications of ferroptosis in diseases

Ferroptosis is involved in the occurrence of several diseases. Studies on ferroptosis inducers and inhibitors have elucidated on the associated disease mechanisms. This section summarizes the mechanisms of ferroptosis inducers and inhibitors in disease occurrence.

Ferroptosis inducers in tumors

A close relationship exists between tumor cells and ferroptosis. Several tumor cells are highly sensitive to drug-induced ferroptosis. Artesunate can specifically induce pancreatic cancer cell lines to produce ROS and activate ferroptosis, thereby inhibiting pancreatic cancer occurrence (59). Moreover, piperamide, cyclophosphamide, and sulfasalazine effectively promoted the death of pancreatic cancer cell lines, MIAPaCa-2 and PANC-1 (60). Sorafenib, which induces ferroptosis in liver cancer, is used in the treatment of advanced liver tumors (61). Sigma-1 receptor (S1R) is highly expressed in hepatocytes, and inhibition of S1R promotes ferroptosis in hepatoma cells (62). The P62-Keap1-NRF2 pathway is important in the inhibition of ferroptosis in hepatocellular carcinoma cells. Erastin induces ferroptosis in gastric cancer cells, whereas cysteine dioxygenase type 1 (CDO1) plays a key regulatory role in ferroptosis (63). CDO1 competitively absorbs cysteine, inhibits GSH synthesis and promotes ferroptosis. Downregulation of the MUC1-C/System Xc⁻ signaling pathway induces ferroptosis in triple-negative breast cancer (TNBC) cells, thereby killing cancer cells, or suppresses self-renewal abilities of cancer cells (64). Furthermore, P53 has been shown to induce ferroptosis in lung cancer A549 cells. Treatment of lung cancer A549 cells with erastin up-regulated and activated P53, thereby activating P21, Bax, and other inhibitory factors of SLC7A11, ultimately inducing ROS accumulation and ferroptosis (65). A study on melanoma reported that miR-137 negatively regulates ferroptosis by directly acting on the glutamine transporter, SLC1A5, in melanoma cells, and miR-137 knockout promotes ferroptosis (66). Moreover, dihydroartemisinin has been shown to induce ferroptosis in head and neck squamous cell carcinoma (15). GPX4 inhibitors including RSL3 and ML-162 induce ferroptosis in head and neck cancer (HNC) cells to varying degrees (67). Therefore, ferroptosis has a great potential in anti-tumor therapy, and this opens up new opportunities for further applications of classical drugs and development of more

effective tumor-targeting drugs.

Ferroptosis inhibitors in neurodegenerative diseases

The main pathophysiological feature of Parkinson's disease is the loss of dopaminergic neurons in the substantia nigra. GSH depletion, lipid peroxidation, ROS levels, and elevated iron levels in dense areas have been reported in brain tissues of patients with Parkinson's disease. Deferoxamine reduces oxidative stress injury and increases dopamine activity, thus improving motor nerve symptoms (68). Ferrostatin-1 reduces neuronal death *in vivo* and *in vitro*, and has a specific protective effect on neurons in patients at their early stages of Parkinson's disease (69). Huntington's disease (HD) is a common neurodegenerative disease. Iron accumulation and abnormal glutamate as well as glutathione levels are major pathological features of HD (70). Studies have reported iron accumulation, lipid oxidation, GSH content, and decreased GPX4 activities in HD animal models and in plasma of HD patients (71). Administration of Fer-1 and iron-chelating agents has been shown to have good protective effects on neurons (72). These findings show that ferroptosis plays an important role in the progression of neurodegenerative HD. Alzheimer's disease (AD), the most common neurodegenerative disease, is characterized by cognitive impairments. Iron levels are significantly elevated in severely damaged hippocampus of HD patients (73). Abnormal iron homeostasis in brain tissues induce brain cells to produce high levels of reactive oxygen species, resulting in oxidative damage to sensitive subcellular structures (74). These findings provide promising ideas for the treatment of neurodegenerative diseases.

Ferroptosis inhibitors in other diseases

Ferroptosis is implicated in the pathophysiological processes of several other diseases. In an ischemic stroke mouse model, GSH levels in neurons were found to have decreased significantly, the degree of lipid peroxidation was elevated and GPX4 activity had been decreased, when compared to control mice. In addition, ferroptosis inhibitors significantly improve the prognostic outcomes for ischemic stroke patients (75). Moreover, ferroptosis is associated with *in vivo* functions in acute renal tubular necrosis and ischemia/reperfusion (I/R) injury, and ferroptosis inhibitors can alleviate this injury (76). Gao *et al.* reported that inhibition of ferroptosis by suppressing glutamine metabolism was




Figure 1 Schematic illustration ferroptosis pathways. Regulatory mechanisms of ferroptosis are divided into three categories. The first pathway regulates iron metabolism, including Iron metabolic pathway, ATG5-ATG7-NCOA4 pathway, and P62-Keap1-NRF2 pathway. Second, it is regulated by the GSH/GPX4 pathway, including P53 pathway, System Xc-/GPX4 pathway, and Glutamine metabolic pathway. Third, it is associated with lipid metabolism, including Lipid metabolic pathway. In addition, Erastin acts on the mitochondria to induce ferroptosis. The FSP1-CoQ10-NAD(P)H and BH4-DHFR pathways exist as independent parallel systems, which cooperates with GPX4 and glutathione to inhibit phospholipid peroxidation and ferroptosis. MVA, mevalonate; GPX4, glutathione peroxidase 4; FSP1, ferroptosis suppressor protein 1; SAT1, spermine N1-acetyltransferase 1; CDKN1A, cyclin-dependent kinase inhibitor 1A/P21; TF, transferrin; TFR1, transferrin receptor 1; DMT1, divalent metal ion transporter 1; ZIP8/14, zinc-iron regulatory protein family 8/14; HSPB1, Heat shock protein β -1; IREB2, iron response element-binding protein 2; HO-1, Heme oxygenase-1; FPN, Ferroportin; PUFAs, Polyunsaturated fatty acids; ACSL4, Acyl-CoA synthetase long-chain family member 4; LPCAT3, phospholipid choline acyltransferase 3; LOX, lipoxygenase; PE, phosphatidylethanolamine; NCOA4, Nuclear receptor coactivator 4; NRF2, nuclear factor erythroid 2-related factor 2; VDACS pathway; GCH1, cyclohydrolase-1; BH4, tetrahydrobiopterin; Gln, L-glutamine; Glu, L-glutamate.

effective in the treatment of I/R-induced tissue damage in isolated wild-type mouse hearts (24). Hangauer *et al.* reported that drug-tolerant persister cancer cells acquire a dependency on GPX4, and loss of GPX4 function results in selective persister cell ferroptotic death *in vitro* and prevents tumour relapse *in vivo* (77). Recently, the relationship between ferroptosis and inflammation has been widely investigated. Ferroptosis-associated necrotizing inflammation has been observed in AKI models and in GPX4 deletion mice (78). GPX4 activation inhibits the activation of arachidonic acid (AA) and NF- κ B pathway in lipid peroxidation-mediated inflammation, thereby

reducing intracellular ROS levels and inhibiting ferroptosis. Therefore, GPX4 activation can be used as a novel anti-inflammatory or cytoprotective therapy.

Conclusions

Ferroptosis plays critical roles in a variety of diseases. However, only a limited number of studies have investigated ferroptosis, and its mechanisms have not been fully elucidated (Figure 1). Various associated problems are yet to be explored: (I) although the regulation of ferroptosis, apoptosis, autophagy and other forms of cell death show a

crosstalk, internal relationships among these different cell death types have not been explored; (II) specific roles of iron ions in ferroptosis should be investigated; (III) mechanisms through which lipid reactive oxygen species cause cell death should also be investigated; (IV) in addition to the described pathways, studies should explore if there are any other pathways that can lead to ferroptosis; (V) basic research findings on ferroptosis should be extended to clinical applications. Studies are currently screening biomarkers to explore the occurrence, development and downstream effects of ferroptosis. Investigating the pathogenesis of ferroptosis and its role in various diseases has enabled the development of targeted treatment methods that have an important theoretical significance and clinical values. Rapid developments in biotechnology and applications of interdisciplinary integration methods will help improve our understanding of ferroptosis.

Acknowledgments

Funding: This study was financially supported by grants from the National Natural Science Foundation of China (81871596), Shanghai Pujiang Program (18PJD062) and the National Natural Science Foundation of China (81670260).

Footnote

Reporting Checklist: The authors have completed the Narrative Review reporting checklist. Available at <https://dx.doi.org/10.21037/atm-21-1595>

Peer Review File: Available at <https://dx.doi.org/10.21037/atm-21-1595>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://dx.doi.org/10.21037/atm-21-1595>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-

commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Li J, Cao F, Yin HL, et al. Ferroptosis: past, present and future. *Cell Death Dis* 2020;11:88.
2. Dolma S, Lessnick SL, Hahn WC, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. *Cancer Cell* 2003;3:285-96.
3. Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. *Chem Biol* 2008;15:234-45.
4. Yagoda N, von Rechenberg M, Zaganjor E, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. *Nature* 2007;447:864-8.
5. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* 2012;149:1060-72.
6. Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. *Cell Death Differ* 2016;23:369-79.
7. Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. *J Hematol Oncol* 2019;12:34.
8. Conrad M, Angeli JP, Vandenabeele P, et al. Regulated necrosis: disease relevance and therapeutic opportunities. *Nat Rev Drug Discov* 2016;15:348-66.
9. Angeli JPF, Shah R, Pratt DA, et al. Ferroptosis Inhibition: Mechanisms and Opportunities. *Trends Pharmacol Sci* 2017;38:489-98.
10. Louandre C, Ezzoukhy Z, Godin C, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. *Int J Cancer* 2013;133:1732-42.
11. Wang W, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. *Nature* 2019;569:270-4.
12. Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. *Cell* 2014;156:317-31.
13. Weiwler M, Bittker JA, Lewis TA, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. *Bioorg Med Chem Lett* 2012;22:1822-6.

14. Lin R, Zhang Z, Chen L, et al. Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells. *Cancer Lett* 2016;381:165-75.
15. Shimada K, Skouta R, Kaplan A, et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. *Nat Chem Biol* 2016;12:497-503.
16. Gaschler MM, Andia AA, Liu H, et al. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. *Nat Chem Biol* 2018;14:507-15.
17. Ooko E, Saeed ME, Kadioglu O, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. *Phytomedicine* 2015;22:1045-54.
18. Ma S, Henson ES, Chen Y, et al. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. *Cell Death Dis* 2016;7:e2307.
19. Yee PP, Wei Y, Kim SY, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. *Nat Commun* 2020;11:5424.
20. Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. *Nat Cell Biol* 2014;16:1180-91.
21. Seiler A, Schneider M, Förster H, et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. *Cell Metab* 2008;8:237-48.
22. Farmer LA, Haidasz EA, Griesser M, et al. Phenoxazine: A Privileged Scaffold for Radical-Trapping Antioxidants. *J Org Chem* 2017;82:10523-36.
23. Krainz T, Gaschler MM, Lim C, et al. A Mitochondrial-Targeted Nitroxide Is a Potent Inhibitor of Ferroptosis. *ACS Cent Sci* 2016;2:653-9.
24. Gao M, Monian P, Quadri N, et al. Glutaminolysis and Transferrin Regulate Ferroptosis. *Mol Cell* 2015;59:298-308.
25. Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. *Nat Chem Biol* 2017;13:91-8.
26. Li C, Deng X, Zhang W, et al. Novel Allosteric Activators for Ferroptosis Regulator Glutathione Peroxidase 4. *J Med Chem* 2019;62:266-75.
27. Bersuker K, Hendricks JM, Li Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. *Nature* 2019;575:688-92.
28. Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. *Nature* 2019;575:693-8.
29. Soula M, Weber RA, Zilka O, et al. Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers. *Nat Chem Biol* 2020;16:1351-60.
30. Kraft VAN, Bezjian CT, Pfeiffer S, et al. GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling. *ACS Cent Sci* 2020;6:41-53.
31. Jiang L, Hickman JH, Wang SJ, et al. Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses. *Cell Cycle* 2015;14:2881-5.
32. Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. *Nature* 2015;520:57-62.
33. Chu B, Kon N, Chen D, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. *Nat Cell Biol* 2019;21:579-91.
34. Ou Y, Wang SJ, Li D, et al. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. *Proc Natl Acad Sci U S A* 2016;113:E6806-12.
35. Jennis M, Kung CP, Basu S, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. *Genes Dev* 2016;30:918-30.
36. Tarangelo A, Magtanong L, Biegging-Rolett KT, et al. p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells. *Cell Rep* 2018;22:569-75.
37. Xie Y, Zhu S, Song X, et al. The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. *Cell Rep* 2017;20:1692-704.
38. Kryukov GV, Castellano S, Novoselov SV, et al. Characterization of mammalian selenoproteomes. *Science* 2003;300:1439-43.
39. Warner GJ, Berry MJ, Moustafa ME, et al. Inhibition of selenoprotein synthesis by selenocysteine tRNASerSec lacking isopentenyladenosine. *J Biol Chem* 2000;275:28110-9.
40. Lin CH, Lin PP, Lin CY, et al. Decreased mRNA expression for the two subunits of system xc(-), SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: Evidence in support of the hypo-glutamatergic hypothesis of schizophrenia. *J Psychiatr Res* 2016;72:58-63.
41. Maiorino M, Conrad M, Ursini F. GPx4, Lipid Peroxidation, and Cell Death: Discoveries, Rediscoveries, and Open Issues. *Antioxid Redox Signal* 2018;29:61-74.
42. Frazer DM, Anderson GJ. The regulation of iron transport. *Biofactors* 2014;40:206-14.
43. Tang D, Chen X, Kang R, et al. Ferroptosis: molecular mechanisms and health implications. *Cell Res* 2021;31:107-25.
44. Bogdan AR, Miyazawa M, Hashimoto K, et al. Regulators of Iron Homeostasis: New Players in Metabolism, Cell

- Death, and Disease. *Trends Biochem Sci* 2016;41:274-86.
45. Sun X, Ou Z, Xie M, et al. HSPB1 as a novel regulator of ferroptotic cancer cell death. *Oncogene* 2015;34:5617-25.
 46. Gammella E, Recalcati S, Rybinska I, et al. Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms. *Oxid Med Cell Longev* 2015;2015:230182.
 47. Kwon MY, Park E, Lee SJ, et al. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. *Oncotarget* 2015;6:24393-403.
 48. Yang WS, Stockwell BR. Ferroptosis: Death by Lipid Peroxidation. *Trends Cell Biol* 2016;26:165-76.
 49. Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. *Nat Chem Biol* 2017;13:81-90.
 50. Shao BZ, Han BZ, Zeng YX, et al. The roles of macrophage autophagy in atherosclerosis. *Acta Pharmacol Sin* 2016;37:150-6.
 51. Zhou B, Liu J, Kang R, Klionsky DJ, et al. Ferroptosis is a type of autophagy-dependent cell death. *Semin Cancer Biol* 2020;66:89-100.
 52. Hou W, Xie Y, Song X, et al. Autophagy promotes ferroptosis by degradation of ferritin. *Autophagy* 2016;12:1425-8.
 53. Mancias JD, Wang X, Gygi SP, et al. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. *Nature* 2014;509:105-9.
 54. Yoshida M, Minagawa S, Araya J, et al. Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis. *Nat Commun* 2019;10:3145.
 55. Dai E, Han L, Liu J, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. *Autophagy* 2020;16:2069-83.
 56. Skonieczna M, Cieslar-Pobuda A, Saenko Y, et al. The Impact of DIDS-Induced Inhibition of Voltage-Dependent Anion Channels (VDAC) on Cellular Response of Lymphoblastoid Cells to Ionizing Radiation. *Med Chem* 2017;13:477-83.
 57. Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. *Hepatology* 2016;63:173-84.
 58. Garcia-Bermudez J, Baudrier L, Bayraktar EC, et al. Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death. *Nature* 2019;567:118-22.
 59. Eling N, Reuter L, Hazin J, et al. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. *Oncoscience* 2015;2:517-32.
 60. Yamaguchi Y, Kasukabe T, Kumakura S. Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. *Int J Oncol* 2018;52:1011-22.
 61. Louandre C, Marcq I, Bouhlal H, et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. *Cancer Lett* 2015;356:971-7.
 62. Bai T, Lei P, Zhou H, et al. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells. *J Cell Mol Med* 2019;23:7349-59.
 63. Hao S, Yu J, He W, et al. Cysteine Dioxygenase 1 Mediates Erastin-Induced Ferroptosis in Human Gastric Cancer Cells. *Neoplasia* 2017;19:1022-32.
 64. Chen MS, Wang SF, Hsu CY, et al. CHAC1 degradation of glutathione enhances cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-eIF2 α -ATF4 pathway. *Oncotarget* 2017;8:114588-602.
 65. Alvarez SW, Sviderskiy VO, Terzi EM, et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. *Nature* 2017;551:639-43.
 66. Luo M, Wu L, Zhang K, et al. miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. *Cell Death Differ* 2018;25:1457-72.
 67. Shin D, Kim EH, Lee J, et al. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. *Free Radic Biol Med* 2018;129:454-62.
 68. Do Van B, Gouel F, Jonneaux A, et al. Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC. *Neurobiol Dis* 2016;94:169-78.
 69. Xiao JJ, Yin M, Wang ZJ, et al. Transplanted Neural Stem Cells: Playing a Neuroprotective Role by Ceruloplasmin in the Substantia Nigra of PD Model Rats? *Oxid Med Cell Longev* 2015;2015:618631.
 70. Agrawal S, Fox J, Thyagarajan B, et al. Brain mitochondrial iron accumulates in Huntington's disease, mediates mitochondrial dysfunction, and can be removed pharmacologically. *Free Radic Biol Med* 2018;120:317-29.
 71. Manoharan S, Guillemin GJ, Abiramasundari RS, et al. The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review. *Oxid Med Cell Longev* 2016;2016:8590578.
 72. Chen J, Marks E, Lai B, et al. Iron accumulates in Huntington's disease neurons: protection by deferoxamine. *PLoS One* 2013;8:e77023.

73. Raven EP, Lu PH, Tishler TA, et al. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging. *J Alzheimers Dis* 2013;37:127-36.
74. Lane DJR, Ayton S, Bush AI. Iron and Alzheimer's Disease: An Update on Emerging Mechanisms. *J Alzheimers Dis* 2018;64:S379-95.
75. Hanson LR, Roeytenberg A, Martinez PM, et al. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. *J Pharmacol Exp Ther* 2009;330:679-86.
76. Linkermann A, Skouta R, Himmerkus N, et al. Synchronized renal tubular cell death involves ferroptosis. *Proc Natl Acad Sci U S A* 2014;111:16836-41.
77. Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. *Nature* 2017;551:247-50.
78. von Mässenhausen A, Tonnus W, Linkermann A. Cell Death Pathways Drive Necroinflammation during Acute Kidney Injury. *Nephron* 2018;140:144-7.

Cite this article as: Zhang JJ, Du J, Kong N, Zhang GY, Liu MZ, Liu C. Mechanisms and pharmacological applications of ferroptosis: a narrative review. *Ann Transl Med* 2021;9(19):1503. doi: 10.21037/atm-21-1595